From the News
Echoes of some news flashes from our collaborators:
Below we summarize press-releases in relation to Tribodies.
Tribodies are multispecific antibody derivatives, with robust and easy development possibilities. Tribodies consist of a fusion of 2 binding elements (such as scFv, or VHH) to a Fab. Tribodies have been shown superior activity as bispecific T-cell engagers, multiparatopic receptor internalization, and multispecific checkpoint inhibitors in immuno-oncology.
Tribodies were created at VIB*, and transferred first to Biotecnol, which later sold technology and a lead product to Chiome Bioscience (CBA-1535 / TB535).
*Schoonjans, R., Willems, A., Schoonooghe, S., Fiers, W., Grooten, J., Mertens, N., 2000. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 165, 7050–7.
Chiome Bioscience Inc. announced that the first patient has been dosed with CBA-1535 in a Phase I clinical trial.
The first part of the trial will evaluate the safety tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients . In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizuma.
This first in human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center (Japan).
Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience (JP) in collaboration with CEINGE (IT)
Tribodies combining blockers for PD-1, PD-L1 and LAG-3 showed enhanced activity on activating lymphocytes as compared to a mix of the parental mAbs, with lower toxicity on normal tissue.
Chiome Bioscience Inc., announced that it has submitted an initial application for a Phase I study on CBA-1535 to the Pharmaceuticals and Medical Devices Agency (PMDA, Japan) on February 16, 2022.
Under this agreement, Biotecnol divested from it’s immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma®. Chiome will continue research and clinical development for Tb535H. In addition, Chiome will continue generating new immune-oncology products using Biotecnol’s Trisoma® technology. Financial details were not disclosed